Abstract
AB001. Development of tumour-targeted therapy for the treatment of adult and paediatric high-grade gliomas
Chinese Clinical Oncology
2024;
13
(Suppl 1)
:AB001
.
(30 August 2024)
AB002. DNA methylation-regulated genes contribute to temozolomide (TMZ) resistance by scaffolding paraspeckle proteins
Chinese Clinical Oncology
2024;
13
(Suppl 1)
:AB002
.
(30 August 2024)
AB003. Clinical analysis of central nervous system (CNS) World Health Organization (WHO) grade 4 gliomas with IDH-mutant versus IDH-wildtype focused on CDKN2A homozygous deletion
Chinese Clinical Oncology
2024;
13
(Suppl 1)
:AB003
.
(30 August 2024)
AB004. Transsylvian approach for radical resection of insular gliomas: emphasizing the importance of the transsylvian approach for elderly patients with Zone II and III insular gliomas
Chinese Clinical Oncology
2024;
13
(Suppl 1)
:AB004
.
(30 August 2024)
AB005. Development of tumour specific therapy for treatment of diffuse intrinsic pontine glioma (DIPG)
Chinese Clinical Oncology
2024;
13
(Suppl 1)
:AB005
.
(30 August 2024)
AB006. The use of magnetic resonance spectroscopy in the differential diagnosis of paediatric intracranial tumours
Chinese Clinical Oncology
2024;
13
(Suppl 1)
:AB006
.
(30 August 2024)
AB007. Intramedullary schwannoma: a rare case report
Chinese Clinical Oncology
2024;
13
(Suppl 1)
:AB007
.
(30 August 2024)
AB008. Intramedullary spinal cord metastases in breast cancer with multiple central nervous system (CNS) metastases: a case report
Chinese Clinical Oncology
2024;
13
(Suppl 1)
:AB008
.
(30 August 2024)
AB009. Distinct clinical profiles and treatment outcomes in invasive pituitary adenoma and Crooke cell tumor: a comparative case report
Chinese Clinical Oncology
2024;
13
(Suppl 1)
:AB009
.
(30 August 2024)
AB010. Analyzing Response Assessment in Neuro-Oncology (RANO) response criteria in WHO grade III anaplastic astrocytomas in comparison to clinician evaluation: a case report
Chinese Clinical Oncology
2024;
13
(Suppl 1)
:AB010
.
(30 August 2024)
AB011. A propensity-score matched prospective study on the impact of tumour treating fields (TTF) on overall survival and quality of life in newly diagnosed WHO grade 4 astrocytoma patients
Chinese Clinical Oncology
2024;
13
(Suppl 1)
:AB011
.
(30 August 2024)
AB012. A phase III randomized trial of gross total resection versus possible resection of fluid-attenuated inversion recovery (FLAIR) hyperintensity lesion on magnetic resonance image for newly diagnosed supratentorial glioblastoma (JCOG2209)
Chinese Clinical Oncology
2024;
13
(Suppl 1)
:AB012
.
(30 August 2024)
AB013. Infantile brainstem high grade glioma: a case report
Chinese Clinical Oncology
2024;
13
(Suppl 1)
:AB013
.
(30 August 2024)
AB014. The accurate classification of high-grade glioma, IDH-wildtype, is based on methylation profiling: a case report
Chinese Clinical Oncology
2024;
13
(Suppl 1)
:AB014
.
(30 August 2024)
AB015. Efficacy and safety of boron neutron capture therapy in managing metastatic spinal tumors: experimental findings
Chinese Clinical Oncology
2024;
13
(Suppl 1)
:AB015
.
(30 August 2024)
AB016. Intracranial tumor characteristics and the incidence of cachexia: a cross-sectional study
Chinese Clinical Oncology
2024;
13
(Suppl 1)
:AB016
.
(30 August 2024)
AB017. NFκB1 regulates FDX1 to facilitate elesclomol-induced cuproptosis against glioblastoma
Chinese Clinical Oncology
2024;
13
(Suppl 1)
:AB017
.
(30 August 2024)
AB018. It’s not always olfactory neuroblastoma—sinonasal undifferentiated carcinoma with frontal base and orbital involvement, a rare disease with poor prognosis: a case report
Chinese Clinical Oncology
2024;
13
(Suppl 1)
:AB018
.
(30 August 2024)
AB019. Detailed analysis of DNA hydroxymethylation observed with the malignant progression of IDH-mutant gliomas
Chinese Clinical Oncology
2024;
13
(Suppl 1)
:AB019
.
(30 August 2024)
AB020. Flagellin synergistically enhances anti-tumor effect of EGFRvIII peptide in a glioblastoma-bearing mouse brain tumor model
Chinese Clinical Oncology
2024;
13
(Suppl 1)
:AB020
.
(30 August 2024)
AB021. Primary diffuse large B-cell lymphoma of the central nervous system: role of imaging in a rare disease—a case report
Chinese Clinical Oncology
2024;
13
(Suppl 1)
:AB021
.
(30 August 2024)
AB022. Management of first recurrence or progression of craniopharyngioma after resection alone: a systematic review and individual-participant data meta-analysis
Chinese Clinical Oncology
2024;
13
(Suppl 1)
:AB022
.
(30 August 2024)
AB023. Early diagnosis and treatment lead to improve survival of glioblastoma patients
Chinese Clinical Oncology
2024;
13
(Suppl 1)
:AB023
.
(30 August 2024)
AB024. Preoperative and postoperative clinical manifestation, hormonal, and imaging profile of sellar region tumor in Dr. Saiful Anwar General Hospital, East Java: a 1-year cross-sectional study
Chinese Clinical Oncology
2024;
13
(Suppl 1)
:AB024
.
(30 August 2024)
AB025. Efficacy of 5-ALA brightness analysis for malignant brain tumor surgery
Chinese Clinical Oncology
2024;
13
(Suppl 1)
:AB025
.
(30 August 2024)
AB026. A rare case report: multiple hemangioblastoma
Chinese Clinical Oncology
2024;
13
(Suppl 1)
:AB026
.
(30 August 2024)
AB027. Distinguishing oligodendroglioma from astrocytoma: a radiological case report
Chinese Clinical Oncology
2024;
13
(Suppl 1)
:AB027
.
(30 August 2024)
AB028. Precision neurosurgery for brain tumors using robotic navigation under exoscope
Chinese Clinical Oncology
2024;
13
(Suppl 1)
:AB028
.
(30 August 2024)
AB029. Mitochondrial dysfunction and impaired growth of glioblastoma cell lines caused by antimicrobial agents inducing ferroptosis
Chinese Clinical Oncology
2024;
13
(Suppl 1)
:AB029
.
(30 August 2024)
AB030. Combined transcranial and endonasal endoscopic approach for sinonasal tumors with intracranial extension: a case series
Chinese Clinical Oncology
2024;
13
(Suppl 1)
:AB030
.
(30 August 2024)
AB031. Endoscopic transsphenoidal surgery for functional pituitary adenoma: shifting paradigms towards pseudocapsule-based resection
Chinese Clinical Oncology
2024;
13
(Suppl 1)
:AB031
.
(30 August 2024)
AB032. The effect of high-dose dexamethasone on systemic immune-inflammation index (SII) in patients with brain tumor, a retrospective study in tertiary hospital in Indonesia
Chinese Clinical Oncology
2024;
13
(Suppl 1)
:AB032
.
(30 August 2024)
AB033. Factors related to neuropathic pain in spinal metastasis tumor patients experiencing cancer pain at Dr. Cipto Mangunkusumo Hospital
Chinese Clinical Oncology
2024;
13
(Suppl 1)
:AB033
.
(30 August 2024)
AB034. Medico-legal ethics dilemma in treatment decisions for intracranial metastasis in a young gravida patient: a case report
Chinese Clinical Oncology
2024;
13
(Suppl 1)
:AB034
.
(30 August 2024)
AB035. Validation of EORTC brain cancer module (EORTC QLQ-BN20) for assessment of health-related quality of life in glioma patients in Singapore
Chinese Clinical Oncology
2024;
13
(Suppl 1)
:AB035
.
(30 August 2024)
AB036. Targeting glioblastoma de-novo purine metabolism to overcome chemoradiation resistance: an interim result of phase 0/1 clinical trial in newly diagnosed and recurrent glioblastoma
Chinese Clinical Oncology
2024;
13
(Suppl 1)
:AB036
.
(30 August 2024)
AB037. Association between systemic immune-inflammation index with hypercoagulable state in primary brain tumor: a retrospective study in Dr. Cipto Mangunkusumo Hospital, Jakarta, Indonesia
Chinese Clinical Oncology
2024;
13
(Suppl 1)
:AB037
.
(30 August 2024)
AB038. Establishing a reliable semi-automated segmentation method for assessing chemoradiotherapy effects on the non-tumoral brain
Chinese Clinical Oncology
2024;
13
(Suppl 1)
:AB038
.
(30 August 2024)
AB039. Malignant transformation of intracranial germinoma to non-germinomatous germ cell tumors—incidence, treatment strategy and outcome: a case report and literature review
Chinese Clinical Oncology
2024;
13
(Suppl 1)
:AB039
.
(30 August 2024)
AB040. A complication of recurrent artery of Huebner infarction after resection of an anterior cerebral artery thrombotic giant intracranial aneurysm: case report and literature review
Chinese Clinical Oncology
2024;
13
(Suppl 1)
:AB040
.
(30 August 2024)
AB041. The morphological changes of paraspinal muscles in adult brachial plexus injury
Chinese Clinical Oncology
2024;
13
(Suppl 1)
:AB041
.
(30 August 2024)
AB042. Combined anti-PD-L1 and anti-VEGFR2 therapy promotes the antitumor immune response in glioblastoma multiforme by reprogramming tumor microenvironment
Chinese Clinical Oncology
2024;
13
(Suppl 1)
:AB042
.
(30 August 2024)
AB043. BRD4 promotes immune escape of glioma cells by upregulating PD-L1 expression
Chinese Clinical Oncology
2024;
13
(Suppl 1)
:AB043
.
(30 August 2024)
AB044. Leptomeningeal metastatic esthesioneuroblastoma: a systematic review with case illustration
Chinese Clinical Oncology
2024;
13
(Suppl 1)
:AB044
.
(30 August 2024)
AB045. E2F6 promotes temozolomide resistance in glioblastoma by enrichment in CARD6 and POSTN promoter region
Chinese Clinical Oncology
2024;
13
(Suppl 1)
:AB045
.
(30 August 2024)
AB046. Dual role of POSTN in maintaining glioblastoma stem cells and immune-suppressive microglia in glioblastoma
Chinese Clinical Oncology
2024;
13
(Suppl 1)
:AB046
.
(30 August 2024)
AB047. Searching for factors relating to long-term survivors of glioblastoma
Chinese Clinical Oncology
2024;
13
(Suppl 1)
:AB047
.
(30 August 2024)
AB048. Evidence of effectiveness of neoadjuvant camrelizumab and apatinib in patients with recurrent high-grade gliomas
Chinese Clinical Oncology
2024;
13
(Suppl 1)
:AB048
.
(30 August 2024)
AB049. Surgery for symptomatic spinal metastases—when, what and how?
Chinese Clinical Oncology
2024;
13
(Suppl 1)
:AB049
.
(30 August 2024)
AB050. Novel treatment vs. standard of care in melanoma-associated leptomeningeal metastases: a systematic review & network meta-analysis
Chinese Clinical Oncology
2024;
13
(Suppl 1)
:AB050
.
(30 August 2024)
AB051. Multiple meningiomas developed outside the radiation field after cranial irradiation: a case report
Chinese Clinical Oncology
2024;
13
(Suppl 1)
:AB051
.
(30 August 2024)
AB052. A multicenter prospective exploratory phase II study of neoadjuvant bevacizumab for newly diagnosed malignant glioma
Chinese Clinical Oncology
2024;
13
(Suppl 1)
:AB052
.
(30 August 2024)
AB053. Lessons from managing an 11-year-old girl with a calvarial neuroblastoma in a resource-limited setting: a case report
Chinese Clinical Oncology
2024;
13
(Suppl 1)
:AB053
.
(30 August 2024)
AB054. Pituitary abscess: a case report of patient after two-time endonasal endoscopic transphenoid approach for pituitary adenoma
Chinese Clinical Oncology
2024;
13
(Suppl 1)
:AB054
.
(30 August 2024)
AB055. Infantile high-grade glioma (IHG)—a case series of Hong Kong experience
Chinese Clinical Oncology
2024;
13
(Suppl 1)
:AB055
.
(30 August 2024)
AB056. Management of a rare case of adult intracranial large temporal mature teratoma in limited neurosurgical care settings: a case report
Chinese Clinical Oncology
2024;
13
(Suppl 1)
:AB056
.
(30 August 2024)
AB057. A rare case of anterior skull base metastasis secondary to follicular thyroid carcinoma presenting as proptosis: a systematic review and illustrative case
Chinese Clinical Oncology
2024;
13
(Suppl 1)
:AB057
.
(30 August 2024)
AB058. Giant bilateral intraventricle ependymoma in pediatric patient with essential tremor as a main symptom: a rare case report
Chinese Clinical Oncology
2024;
13
(Suppl 1)
:AB058
.
(30 August 2024)
AB059. Molecular signatures for survival prediction in glioma: a prospective, real-world data analysis
Chinese Clinical Oncology
2024;
13
(Suppl 1)
:AB059
.
(30 August 2024)
AB060. Autophagy-associated biomarkers ULK2, UVRAG, and miRNAs miR-21, miR-126, and miR-374: prognostic significance in glioma patients
Chinese Clinical Oncology
2024;
13
(Suppl 1)
:AB060
.
(30 August 2024)
AB061. Oligodendroglioma in a 10-year-old girl with history of mediastinal mass and radiotherapy: a case report
Chinese Clinical Oncology
2024;
13
(Suppl 1)
:AB061
.
(30 August 2024)
AB062. Investigating miR-21 as a non-invasive prognostic biomarker in glioma patients
Chinese Clinical Oncology
2024;
13
(Suppl 1)
:AB062
.
(30 August 2024)
AB063. NF2 expression is linked to meningioma location and visual symptoms in Indonesian patients
Chinese Clinical Oncology
2024;
13
(Suppl 1)
:AB063
.
(30 August 2024)
AB064. Two case reports & review of literature: perioperative surgical management of symptomatic large non-functioning pituitary masses in early pregnancy
Chinese Clinical Oncology
2024;
13
(Suppl 1)
:AB064
.
(30 August 2024)
AB065. Basal ganglia germ cell tumor presenting with visual loss in adult: a case report
Chinese Clinical Oncology
2024;
13
(Suppl 1)
:AB065
.
(30 August 2024)
AB066. From imaging to molecular diagnosis: VASARI magnetic resonance imaging features to predict isocitrate dehydrogenase mutation status in glioma
Chinese Clinical Oncology
2024;
13
(Suppl 1)
:AB066
.
(30 August 2024)
AB067. New drug development for the use of PARP1-E2F1 transcriptional inhibitors in the treatment of glioblastoma
Chinese Clinical Oncology
2024;
13
(Suppl 1)
:AB067
.
(30 August 2024)
AB068. Psychiatric disorder in central nervous system tumor patients and its related factors
Chinese Clinical Oncology
2024;
13
(Suppl 1)
:AB068
.
(30 August 2024)
AB069. Type of personality and cancer-related pain in central nervous system (CNS) tumor patients: a cross-sectional study
Chinese Clinical Oncology
2024;
13
(Suppl 1)
:AB069
.
(30 August 2024)
AB070. Roles of neutrophil to lymphocyte ratio in differentiating glioblastoma from brain metastasis
Chinese Clinical Oncology
2024;
13
(Suppl 1)
:AB070
.
(30 August 2024)
AB071. Predictive value of plasma microRNA-10b and microRNA-21 on chemotherapy toxicity, recurrence, and overall survival in high-grade glioma patients treated with temozolomide
Chinese Clinical Oncology
2024;
13
(Suppl 1)
:AB071
.
(30 August 2024)
AB072. Intraoperative mapping and preservation of executive functions in awake craniotomy: a systematic review
Chinese Clinical Oncology
2024;
13
(Suppl 1)
:AB072
.
(30 August 2024)
AB073. Electrocorticography high-gamma dynamics during intraoperative hand movement mapping
Chinese Clinical Oncology
2024;
13
(Suppl 1)
:AB073
.
(30 August 2024)
AB074. Propensity-score matched analysis to evaluate the safety and utility of intraoperative cell-salvaged autologous blood transfusion in metastatic spine tumour surgery
Chinese Clinical Oncology
2024;
13
(Suppl 1)
:AB074
.
(30 August 2024)
AB075. When would minimally invasive spinal surgery not be preferable for metastatic spine disease?—a narrative review
Chinese Clinical Oncology
2024;
13
(Suppl 1)
:AB075
.
(30 August 2024)
AB076. Underutilization of epilepsy surgery in Pakistan: 10-year experience from the only comprehensive epilepsy center in the country
Chinese Clinical Oncology
2024;
13
(Suppl 1)
:AB076
.
(30 August 2024)
AB077. An evaluation of prognostic scoring systems for survival in a surgically treated cohort of 318 metastatic spine tumour surgery patients
Chinese Clinical Oncology
2024;
13
(Suppl 1)
:AB077
.
(30 August 2024)
AB078. Patterns of treatment delay in patients with symptomatic metastatic epidural spinal cord compression
Chinese Clinical Oncology
2024;
13
(Suppl 1)
:AB078
.
(30 August 2024)
AB079. Whole-brain radiotherapy versus high dose chemotherapy with autologous stem-cell transplantation for consolidation therapy in primary central nervous system lymphoma
Chinese Clinical Oncology
2024;
13
(Suppl 1)
:AB079
.
(30 August 2024)
AB080. High-dose methotrexate with and without intra-thecal methotrexate and whole-brain radiotherapy for primary central nervous system lymphoma: a systematic review
Chinese Clinical Oncology
2024;
13
(Suppl 1)
:AB080
.
(30 August 2024)
AB081. Experience using CFR-PEEK implants in metastatic and primary spine tumour surgery: a single centre retrospective study
Chinese Clinical Oncology
2024;
13
(Suppl 1)
:AB081
.
(30 August 2024)
AB082. Navigating barriers to epilepsy surgery: a national survey of patient and neurologist perspectives
Chinese Clinical Oncology
2024;
13
(Suppl 1)
:AB082
.
(30 August 2024)
AB083. Epilepsy and low-grade glioma-seizure control after surgical resection: a retrospective cohort study
Chinese Clinical Oncology
2024;
13
(Suppl 1)
:AB083
.
(30 August 2024)
AB084. T2-fluid-attenuated inversion recovery (T2-FLAIR) mismatch as predictive MRI findings of diffuse astrocytoma: a case report
Chinese Clinical Oncology
2024;
13
(Suppl 1)
:AB084
.
(30 August 2024)
AB085. Trans-cortical trans-ventricular approach to pineal tumors: a case series
Chinese Clinical Oncology
2024;
13
(Suppl 1)
:AB085
.
(30 August 2024)
AB086. Retractor-less supraorbital approach for minimally exposed meningioma resections: a case report
Chinese Clinical Oncology
2024;
13
(Suppl 1)
:AB086
.
(30 August 2024)
AB087. Rectosigmoid approach for cerebellopontine angle tumors: what have we learned so far?
Chinese Clinical Oncology
2024;
13
(Suppl 1)
:AB087
.
(30 August 2024)
AB088. Spinal cord diffuse midline glioma in adults: a case report and literature review
Chinese Clinical Oncology
2024;
13
(Suppl 1)
:AB088
.
(30 August 2024)
AB089. Improving decision-making in traumatic brain injury patients via 3D volumetric analysis of epidural haematoma
Chinese Clinical Oncology
2024;
13
(Suppl 1)
:AB089
.
(30 August 2024)
AB090. A rare case report: spheno-orbital meningioma with dural involvement
Chinese Clinical Oncology
2024;
13
(Suppl 1)
:AB090
.
(30 August 2024)
AB091. Establishment and application of brainstem glioma organoids
Chinese Clinical Oncology
2024;
13
(Suppl 1)
:AB091
.
(30 August 2024)
AB092. Imaging the histopathology subtypes of the growth hormone-secreting pituitary neuroendocrine tumor
Chinese Clinical Oncology
2024;
13
(Suppl 1)
:AB092
.
(30 August 2024)
AB093. Pixel-wise classification of glioma using deep learning for accurate tumour mapping on magnetic resonance imaging
Chinese Clinical Oncology
2024;
13
(Suppl 1)
:AB093
.
(30 August 2024)
AB094. Association of body mass index with grading and survival of glioma patients
Chinese Clinical Oncology
2024;
13
(Suppl 1)
:AB094
.
(30 August 2024)
AB095. Methylation class infant-type hemispheric glioma with CDKN2A/B deletion: a rare case report
Chinese Clinical Oncology
2024;
13
(Suppl 1)
:AB095
.
(30 August 2024)
Disclosure:
The supplement “Abstract Book for the 19th Asian Society for Neuro-Oncology Annual Meeting” was commissioned by the Editorial office, Chinese Clinical Oncology without any sponsorship or funding.
